In this edition, ‘The 10 Most Trusted Vaccine Solution Providers, 2020’ CIO Look has shortlisted various healthcare organizations which are playing an important role towards the global healthcare system.

1. Vaccine
Solution Providers,
2020
10
Most Trusted
T
h
e
DECEMBER 2020
NEXELIS
An Agile Approach to Bioanalysis
The Age of DNA
Nanotechnology
Tech Outlook
Caring for the elderly
amid covid-19
Leaders Viewpoint
Evolving Future Of The
Biopharmaceutical Industry
New Horizons

4. A Light of Hope
ealth and medical scholars have defined
Hvaccination as one of the best ten achievements
of public health in the 20th century. Vaccines
work by imitating an infective agent also called viruses,
bacteria or other microorganisms that can cause a
sickness. It prepares the immune system to rapidly and
effectively counter against the disease.
Usually, vaccines have done this by presenting a
weakened form of an infectious agent that allows the
immune system to build a memory of it. This way, the
immune system can quickly recognize and fight it
before it makes body ill. That’s how some existing
COVID-19 vaccine candidates are being designed.
A vaccine for COVID-19 will be a critical instrument to
bring pandemic under control by using combined and
effective testing and existing prevention measures.
There are several promising vaccine candidates in the
pipeline, some of them are under review for approval
and the Pfizer/BioNTech and Moderna vaccines are
already approved for use. The race for providing a safe
and effective vaccine has entered into a new phase.
According to a report, the world class association like
UNICEF is sharing its knowledge as the largest single
vaccine buyer in the world by cooperating with the
PAHO Revolving Fund and the COVID-19 Vaccine
Global Access Facility (COVAX Facility).
But it’s important to remember that the journey from
developing a vaccine to licensing it, producing it at scale
and using it widely is a long one. Once a vaccine
receives the required approval, it will then be critical
EDITOR’S NOTE

5. that it is made accessible, in a timely and equitable manner, to reach those that need it
most. That’s where UNICEF and its partners come in.
So, in this edition, ‘The 10 Most Trusted Vaccine Solution Providers, 2020’ CIO Look has
shortlisted various healthcare organizations which are playing important role towards
global healthcare system.
The cover featured Nexelis which has deep expertise in the disciplined field of vaccines,
large molecules, immunotherapies and biomarkers, with a strong reputation for
accelerated results, enabled by state-of-the-art platforms. The company excels by
combining robust protocols with scientific discipline, human agility and client partnership
in order to answer the most demanding mission requirements.
Also, while flipping the pages, don’t forget to go through the articles and CXOs written by
our in-house editorial team and industry experts respectively.
Happy Reading!
Abhishaj Sajeev
abhishaj@ciolook.com
Vaccine
Solution Providers,
2020
10
Most Trusted
T
h
e

6. NEXELIS
An Agile Approach to Bioanalysis
10
COVER STORY
52
ARTICLE
New Horizons
Evolving Future Of The
Biopharmaceutical Industry
C
O
N
T
E
N
T
S

7. 36
Leaders Viewpoint
Caring for the elderly amid covid-19
Tech Outlook
The Age of DNA
Nanotechnology
Celerion
Translating Scientific Ideas into
Potential Medicines
Healthcare Viewpoint
The Impacts of Pandemic in
Pharma and Biotch Laboratory
BSV
Setting benchmarks in
patient outcomes
CMIC, Inc.
Ascending Zeniths of
Global Success
44
56
40
32
48

8. CONTENT
Senior Editor Alan Swann
Executive Editors Rohit Chaturvedi
Alex Spellman
DESIGN
Visualizer Dave Bates
Art & Design Director Sanket Zirpe
Associate Designer Kushagra Gupta
SALES
Senior Sales Manager Kshitij S.
Customer Success Manager Jack Ryan
Sales Executives John, Kane, Irfan
TECHNICAL
Technical Head Aditya K.
Technical Consultant Victor Collins
December, 2020
Copyright © 2020 CIOLOOK, All
rights reserved. The content
and images used in this
magazine should not be
reproduced or transmitted in
any form or by any means,
electronic, mechanical,
photocopying, recording or
otherwise, without prior
permission from CIOLOOK.
Reprint rights remain solely
with CIOLOOK.
FOLLOW US ON
www.facebook.com/ciolook
www.twitter.com/ciolook
WE ARE ALSO AVAILABLE ON
Email
info@ciolook.com
For Subscription
www.ciolook.com
CONTACT US ON
Abhishaj Sajeev
Editor-in-Chief
sales@ciolook.com
abhishaj@ciolook.com

10. Brief
Company Name
MEVAC
me-vac.com
Triox Nano
smartriox.com
Blue Water
Vaccines, Inc
bluewatervaccines.com
Blue Water Vaccines, a Greater Cincinnati startup, has received
$7 million in financing to commercialize a single vaccine that
could offer protection against all types of flu.
MEVAC is the first and largest private factory for
manufacturing vaccines in Egypt, the Middle East and Africa
with International Accreditations.
TrioxNano has developed and patented a programmable nano
delivery platform that can carry different medications,
including chemotherapies, to their target tissue. The technology
uses nanoparticles based on DNA machinery.
Bharat Serums and
Vaccines Ltd
bharatserums.com
Bharat Serums And Vaccines Limited is one of the fastest
growing bio pharmaceutical companies in India.
SANJIV NAVANGUL
Managing Director
and CEO
Joseph Hernandez
CEO
2A Pharma
AB 2apharma.comon
2A Pharma is a clinical stage Swedish/Danish
biopharmaceutical company focused on discovering,
developing and commercialising novel, cost effective
prophylactic and therapeutic vaccines based on its patented
AAVLP platform.
Preben Bruun-Nyzell
CEO
Maroba Aged Care
maroba.com.au
Maroba is a caring community for self-care, semi-independent
and full residential care for the aged. Visitors call it
“exceptional” and “amazing”.
Viv Allanson
CEO
Dr. Roy Farfara
Founder
Celerion
celerion.com
Celerion’s commitment to swift, exceptional research through
translational medicine.
Zori Cheshmedzhieva
Vice President Global
Clinical Development
Magdy Elsayed
CEO
CMIC, Inc
cmicgroup,com
HRBoost is Shared Services HR firm specializing in building
HR from scratch and implementing practices that add value.
HRBoostLLC
hrboost.com
Metrendalytics
Consultants
metrendalytics.com
The company specializes in the development of a variety of
cost-efficient and scalable cloud-based applications for the
centralization, aggregation, and standardization of data for real
time analytics.
Jahanara Miotto
President
Featuring Person
Nexelis
nexelis.com
Nexelis is a leading provider of assay development and
advanced laboratory testing services in the infectious diseases,
metabolic diseases, and oncology fields.
Benoit Bouche
CEO

12. NEX
An Agile Approa

13. XELIS
ach to Bioanalysis
COVER STORY

14. Cover Story
Key milestones of Nexe
here is a unique strength in numbers. We
Tunderstand more and more easily together, and
the ongoing pandemic underlines the crucial
position of international cooperation on science and
technical frontiers. In recent months, our doctors,
clinicians, scientists, and medical experts from all walks
of life have collaborated relentlessly to tackle the
pandemic of coronavirus in a spirit of cooperation that
is beyond precedent.
The necessity for both simultaneous attempts to
generate several prospective candidates and the need
for fast, large-scale production and global delivery are
crucial to the evaluation of vaccinations for every type
of disease. And that's what our edition The 10 Most
Trusted Vaccine Solution Providers, 2020 is all about. We
are on an adventure to extract out all the companies
making revolutionary developments in the industry.
And we can't be more pleased to commence this issue
with Nexelis, a preferred partner of choice for
companies working on the vaccine development.
Despite being a relatively young Contract Research
Organization (CRO) firm, Nexelis has become the
preferred partner in vaccine development in no time.
With its roots deep in vaccine research, with many of its
experts originating in GSK vaccines, Nexelis is a

15. elis story
COVER STORY
dynamic and motivated company dedicated to apply its
knowledge, agility and drive to further support vaccine
efforts against diseases like COVID-19, as well as
servicing other areas in immunology where new
therapies are urgently needed to save lives.
The CRO firm brings its unrivalled expertise in
immunology to the industry. With assay development
and advanced laboratory testing, the company provides
services to companies seeking solutions in the
infectious diseases, metabolic diseases, and oncology
arenas. Nexelis has become a testing lab of choice for
top 10 global pharmaceutical, innovative biotechnology
companies, and governmental or non-governmental
organizations funding the development of vaccines
targeting emerging countries, which use the CRO's
services to help develop lifesaving innovations.
The Inception Saga
The company came into existence as a meeting of
minds, when NEOMED-LABS was spun-off from GSK
Vaccines in 2015, partnered with Ampersand Capital in
2018, acquired Pacific Biomarkers the same year and
PairImmune in 2019.This group combines over 10 years
of bioanalysis, 20 years of vaccine and 25 years of
biomarker experience. Through new strategic
acquisitions, Nexelis continues to grow and bring in
important areas of expertise, solidifying its leadership
position in the immunology field.
Earlier this year, Belgian specialty immunogenicity and
immuno-oncology testing ImmunXperts and
Indianapolis based bioanalytical ligand binding and
mass spectrometry laboratories joined the group,
further extending its portfolio of services. These
acquisitions also provide Nexelis a global presence with
3 sites in North America: Laval, QC; Indianapolis, IN;
Seattle; WA and 2 sites in Europe: Gosselies, Belgium
and Porton Down, the UK (through a partnership with
PHE, Public Health England). We understand that the
company will add a third site in Europe in the months to
come through another acquisition to be announced
before the end of the year.
A passionate leadership team
Benoit Bouche, the CEO of Nexelis, has spent over 30
years growing in healthcare business. His dual
professional background in both science and business
has provided him with an in-depth knowledge of all
aspects of a healthcare venture stage company. As an
entrepreneur, investor, advisor, and board member, he
has honed his expertise in dealing with the challenges
that arise when a company experiences a growth spurt.
It is his experience that has proven invaluable for the
meteoric rise of Nexelis.
Bouche joined NEOMED-LABS in 2017. His assignment
was to transform a 55-person vaccine R&D unit, into a
global services provider for immuno-centric advanced
lab testing. With an MBO backed by Ampersand Capital
in July 2018, and a number of organic and inorganic

16. initiatives, the company more than sextupled its size in
two years and a half.
He says, “At Nexelis, we offer a distinctive approach
centered on this openness to creativity and innovation
which allows us to be very flexible in our pursuits. This
approach, in turn, generates enthusiasm from our scientists,
collaborators and clients. Personally, I view politics and lack
of transparency as the main roadblocks to efficiency in a
corporation. That is why I have always tried to promote this
culture, whereby we encourage our specialists to exchange
freely with colleagues and partner with clients in a spirit of
collaboration and transparency. As a result, there's no
overlong process or heavy hierarchy at Nexelis. We get
things done!”
Luc Gagnon, VP Vaccine Sciences
Armed with over 20 years of experience, Luc Gagnon is
in charge of scientific operations at Nexelis in the
vaccines field. He is responsible for developing assays
supporting vaccines and biologics through the various
phases of the clinical trials. Since its very beginnings,
Luc has worked as VP of Vaccine Sciences, making the
transition from the pharmaceuticals to a CRO following
GSK 's 2015 spin-off.
GSK exchanged the oncology business in 2015 with the
business of Novartis vaccines. As a result, GSK had to
abandon the Laval facility in Canada for so many R&D
sites worldwide. However, the pharmaceutical industry
was conscious of the tremendous potential of the Laval
experts and sponsored their conversion into a single
CRO.
Luc says, “At the Laval GSK site, we almost had the full
chain of vaccine testing available, from early discovery of
new antigens up to the pre-GMP production, and even a
clinical site where human samples were tested to assess
immune responses. We were able to take all that expertise
and convert it into a new CRO venture.”
In the first three years Nexelis-initially called
NEOMED-LABS-has begun to travel and was given the
buildings and all the instruments and $25 million in
financing. 55 workers entered the newly established
organization in terms of professionals, all of them with
more than 15 years of vaccine evaluation experience.
“As I always say to potential partners: we're a young CRO
with an old soul, thanks to our very experienced staff. The
core team was highly versed in analyzing samples
generated in phase I up to phase IV clinical trials.
Furthermore, we have access to the best equipment. We
have fully automated systems that can tackle large series of
clinical samples while maintaining both the integrity and
quality of the testing being performed,” he adds.
He further continues with “In terms of quality, we also
stay true to our pharma roots. The first time we were
audited to obtain our GCLP certification, we were told we
were overly engineered. Usually companies need to take
action to reach a certain line, but we were already way
above the line! So, we have the whole package, combining
our eye for quality with the scientific expertise and the
instruments. This makes us one of the best players for
vaccines and immunology specialty labs in the market.”
Nexelis has complete assay packages that allows
collaborators to produce all data required to submit for
new vaccines. Their collective strategy is one of the
keys for Nexelis growth. They follow the approach of a
collaborator instead of a customer support provider
during projects.
Luc asserts, “In every project, we strive to be an extension
of our partner's lab. We're not a CRO where it's 'our way or
“The COVID-19 has placed our labs at the heart of multiple R&D initiatives
with an incredible number of projects initiated in a short period of time. This,
while we have continued to work on our preexisting projects. Agility and
speed have been absolutely key.”
“

17. COVER STORY
Benoit Bouche
President & CEO

18. the highway'. We're always willing to further improve on the
science, process, or performance of the assay. Working as
partners also means that we can openly discuss things
without being afraid to challenge each other on important
decisions. We are confident that our opinions matter and
that our input is beneficial to our partners, as our scientists
are so experienced. This collaborative relationship lets us
achieve the best possible outcome without the risk of any
caveat or grey zone. We're not only executing; we're also
providing advice based on our experience in the vaccine
field.”
The SARS-CoV-2 soon began to disperse across the
world at the beginning of 2020. This challenge has been
recognized by the Nexelis team early and committed
collaborators have begun to search into solutions. In
battling this deadly pandemic, the organization has
played a leading role.
“We were able to very quickly develop new assays that
measure the extent to which candidate vaccines elicit an
immune response to SARS-CoV-2. Because we already had
a general approach to developing such assays, we were able
to fast-track the development. This is something we are
capable of doing for any new health threat that arises
unexpectedly. It's an important lesson we've learned from
this crisis: we all need to develop more generic approaches
and stay vigilant for potential new pandemics, so we can
start developing tools in time like we managed to do for the
COVID pandemic. Our assays are now becoming the gold
standard, used around the world. I'm also proud to say that
we initially funded this work internally and obtained the
support of the Bill and Melinda Gates foundation in this
initiative, out of a desire to quickly help tackle this
pandemic issue,” cites Luc.
The Nexelis SARS-CoV-2 research forced several
businesses and industries to invest in COVID-19
vaccinations and therapies at the front and center of
the market.
He comments, “We are also supporting CEPI (the Coalition
for Epidemic Preparedness Innovation), a global
partnership launched in 2017 to develop vaccines to stop
future epidemics. CEPI is now also sponsoring initiatives to
accelerate the development of COVID-19 vaccines. Our
assays, to determine immunogenicity of candidate vaccines,
will be transferred to six other labs around the world, which
we will be managing at distance in terms of quality.”
The business has grown steadily since its creation in
2015 by integrating internal innovations and external
acquisitions. The Nexelis team has quadrupled in scale
in 18 month and will have sextupled in two years and a
half at the end of the year 2020. Additional Nexelis
locations, based on biomarker studies in Seattle, and
Belgium with experience in early in vitro and in vivo
preclinical development are situated in addition to the
Laval location in Canada where vaccine research is
carried out. Nexlis often collaborates with Public
Health England – Porton Down following entering into
strategic relationship in July 2019. Nexelis has become
an immunocentric CRO with a robust reach.
“Despite the boom in COVID-19 vaccine research, the
vaccine field remains limited to a few key players,
particularly when compared to larger domains such as
immuno-oncology or cell and gene therapy. With our strong
background in vaccines, we have quickly become the
number one partner for this field. Now, with the growing
demand of other growing immunology fields, we are
working hard to extend our services in other domains. The

19. COVER STORY
aim is, of course, to become the partner of choice for these
larger fields as well. To do so, we have been investing
heavily in our capability to perform next-generation
sequencing and qPCR, and measure gene and biomarker
expression using flow cytometry or cellular immunology. In
addition to this internal growth, we're purchasing
companies that allow us to build new capabilities rapidly
and incorporate further expertise in our scientific team,” he
asserts.
Adding further to the sustainable future, he says, “For
our vaccine business, international growth is a key focus.
We're working on setting up centralized labs in Europe and
Asia, reducing the costs of shipping samples around the
world. This saves not only money, but also reduces both the
time and environmental impact. Our new site in Belgium
already gives us a footprint in Europe, but the goal is to
expand further geographically. In that aspect, we will be not
only growing horizontally with different pillars, but also
vertically to have a broader presence around the world. All
of this growth will bring new benefits to our partners, and
further cement our position as the top CRO for advanced
laboratory testing services.”
Greg Kulnis, Senior Director of Customer Solutions
Greg Kulnis is the first in line for sponsors in the
vaccines field as a Senior Director of Customer
Solutions at Nexelis. Combining a research background
with many years of business development experience,
he is the perfect fit to connect the operational and
commercial departments within Nexelis. Kulnis
expresses some of his favorite facets of Nexelis work
and his confidence in the vaccinations and medicines
the organization aims to produce.
The team of Customer Service aims at supplying
Nexelis consumers with the greatest consumer
experience. A core component of this step is to identify
what prospective customers need and link them to the
right research tools inside the organization.
Greg says, “We have a number of experts in different fields,
meaning we can always find a good fit for new partners. For

20. Greg Kulnis
Senior Director
of Customer Solutions

21. COVER STORY
example, we have Luc Gagnon, our VP of Vaccine Sciences
for all vaccine related projects. For preclinical development,
we can rely on Danielle Poirier, who leads our preclinical
team in Laval, or Bassam Hallis of Public Health England.
For early in silico or in vitro immunogenicity assessment, we
leverage the insights of Sofie Pattijn from our newly
acquired division in Belgium.”
“I worked in the lab for a number of years prior to moving to
the commercial side, and I've always appreciated being able
to establish a conversation between two well-aligned
experts. For a new client, it's important that we are
confident in all of the business areas, but what really instills
trust in our organization is connecting the experts and
allowing them to engage in those in-depth exchanges. It
helps demonstrate our competence and instils confidence in
our ability to deliver the project in exactly the right way and
according to the desired timelines.”
Nexelis is set up to foster cohesive cooperation across
the globe. The organization is built so that each of the
sites has their own specialty without significant overlap
in expertise.
“Our biomarker experts in Seattle remain our biomarker
experts. If we have a vaccine-based project that's looking to
assess a biomarker, we don't rely on the resources in Laval,
but instead reach out to the team in Seattle where that is
their true core expertise. The same applies for mass
spectrometry which is the core expertise of the Indianapolis
team led by Shelby Anderson. This way we ensure that our
clients are accessing the top experts at all times, no matter
the area and geographical location,” says Greg.
Like a sharp blade, Nexelis uses its limited scale and
professional scientists to perform the utmost. The
company's emphasis on immunologic tests, usually for
large molecular molecules, has been improved over the
years. The business has taken on a strong leadership
role in this region due to its long-standing expertise.
The reduced scale of the organization often helps the
team to handle consumer initiatives much more flexibly
than the bureaucracy-laden activities of the bigger,
broader CRO.
He says, “Since we are rather specialized in what we do,
and we don't try to cover a large number of other disease
areas, we are able to house all services under one roof and
still be very nimble in our approach to client studies. We are
not bogged down by the corporate machinery of larger
companies, where the requirement to conform to standard
processes causes delays for clients. We're adaptable and
very flexible in serving the needs of our clients. As a
company grows, you need to make more of a concerted
effort to maintain that agility, which has definitely been the
case with the Nexelis leadership team.”
The strengths of Nexelis include the firm's contribution
to rigorous research and performance. The
preservation of these expectations ensures that the
finest research minds are drawn, a challenge for which
the Nexelis team has a variety of cards up its sleeve.
Greg asserts, “One of the key opportunities we offer
researchers who join our team is being able to interact
directly with the top scientific minds in the companies we
work with. For instance, if we're talking to a large
pharmaceutical company, a Nexelis researcher would likely
be working with a principal scientist in their immunology
group, and when we're working with smaller partners, our
researchers are often personally engaging with their CSO.
This opportunity, to liaise and exchange ideas directly with
the world's top experts, is a real plus of working at Nexelis
as it is not usually possible for most researchers at larger
CROs.”
“We have the whole package, combining our eye for quality with the scientific
expertise and the instruments. This makes us one of the best players for
vaccines and immunology specialty labs in the market
“

22. Respiratory
Seasonal & Pandemic Influenza
Haemophilus influenzae
Respiratory Syncytial virus,
Neisseria meningitidis
Streptococcus pneumoniae
Bordetella pertussis
Corynebacterium diphtheriae
Rhinovirus
Enteric
Escherichia coli
Shigella spp.
Clostridium difficile
Rotavirus
Salmonella typhimurium
Vector/Zoonotic
Chikungunya
Zika
Dengue
Malaria
Yellow Fever
Sexually Transmitted
Cytomegalovirus
Herpes
Hepatitis B
Other Infectious
Diseases
Human papilloma virus
Adenovirus
Adeno-associated
virus (AAV)
Measles
Mumps
Rubella
Varicella Zoster
Tetanus
Staphylococcus aureus
Streptococcus agalactiae (GBS)
Lymphocytic choriomeningitis
mammarenavirus (LCMV)
Vaccinia
Vaccine credentials
“The diversity of the projects that our researchers get to
work on is also a real motivator. When I started my career
at Merck, I worked on the rotavirus vaccine for 5 years,
without any variation. Whereas within the span of 5 days, a
scientist developing new assays at Nexelis could be working
on a meningococcal, pneumococcal, rabies and a
chikungunya vaccine, just to name a few. This diversity of
assays leads them to really have a deeper understanding of
different infectious disease agents, and not be pigeonholed
within a particular assay. They are able to build a
tremendously broad expertise and translate that into
projects that are geared towards saving lives.”
Nexelis operates in a large variety of bacterial and viral
disease environments, where people require successful
vaccinations urgently. The organisation also built a
toolbox for the wide spectrum of pathogens that is
appropriate for the differing needs of multiple
researchers.
He cites, “Right now, some of the biggest areas that we are
focusing on are bacterial targets like pneumococcal and
meningococcal vaccines. However, we have also been
working on viral diseases for a number of years, like RSV for
example. All of these diseases are severe issues that
urgently need vaccines to protect the vulnerable. RSV is
particularly pressing, as the disease is literally the second
most common cause of death for children under the age of
one, only beaten by malaria.”

23. COVER STORY
While Nexelis' disease foci are typically client-driven,
some developments are funded by the company itself.
“Our chikungunya efforts were actually self-funded, a
development that we then offered to different commercial
partners. We chose to fund this particular project upfront as
chikungunya is a neglected tropical disease, primarily
affecting people in the world's poorer regions, spread by
mosquitos in Africa, Asia, and India. Because for us it is not
just about serving client needs; it is also about making a
positive difference to people,” says Greg.
This ability to adjust their assays to address widely
varying diseases is a real strength of Nexelis'.
He adds, “Having the flexibility to shift team members
between projects and possessing a core expertise in
different methodologies is significantly beneficial to both
Nexelis and our clients. One of the great things about the
infectious disease model and the assessments that we
perform is that they are pathogen agnostic, so they can be
used for a range of different diseases. Whether it's E. coli or
Shigella, they do remarkably similar things at the
immunological level. Naturally, with a bacterium you are
going to be measuring some different things than you would
with a virus, but that's why we have our specialized teams
in place to make sure we're addressing what's needed in
each case. Transferring the assays from one bacterium to
another also takes some work, but you're not trying to
completely understand the biology of the different
pathogens every time; you're just trying to measure the
body's immune response to it, which is usually a well-
defined process by the time you get to a vaccine candidate.”
Having a full portfolio of services in-house enables
Nexelis to respond rapidly to emerging health threats.
The ongoing SARS-CoV-2 pandemic has proved to be an
excellent example of the company's capabilities.
Greg asserts, “We quickly recognized SARS-CoV-2 as a
major event that we needed to act on. Together with
Benoit, Luc, and the support of our Board of Directors, we
decided to self-fund the efforts to develop assays to
determine if vaccine candidates could elicit an immune
response. We rapidly got these up and running and offered
them commercially to the various sponsors. Thanks to that
quick decision making, our assays are very advanced
compared to others and have been adopted by the global
community. The choice to self-fund their development was
however more of a humanitarian decision than a
commercial one. Getting these candidate vaccines to
market faster will be a great benefit to everybody.”
“In developing the SARS-CoV-2 assays, we were able to
benefit from the breadth of our own services. For example,
in the early stages of the outbreak, it was exceedingly
difficult to obtain a commercial source of the different
SARS-CoV-2 antigens that we needed. They are critical for
the assays and, thanks to our protein engineering team, we
were able to develop all those materials in-house. This
allowed us to act faster than when having to wait on a
commercial supplier. Producing the antigens in-house also
prevented the risk of supply chain breakdown, which would
have slowed down the process. We were just able to walk it
down the hall, turn it over to our immunochemistry team
and say: “Here you go, please start developing your ELISA.”
“Another key factor in our success was a lot of sacrifice,
hard work and long hours by the team. Because the team
has worked together for almost 20 years now, we could
really leverage our best practices, allowing us to push these
assays forward in an extremely accelerated timeframe
without jeopardizing the quality. It was really through the
dedication of the team, that these assays were made
possible.”
Infectious diseases
Vaccines
Antiviral drugs
Oncology
Immunotherapies
Gene and cell therapies
Metabolic diseases
Metabolic syndrom, diabetes and
dyslipemia
Inherited metabolic disorders
Therapeutic Focus

24. Kulnis says the pandemic has also changed the nature
of some client projects.
“Because of the urgency of the pandemic, we're getting
involved in COVID-19 projects at a much earlier stage than
we typically would. Sometimes the companies don't even
have their antigen selected yet, or they don't know what
their formulation is going to look like. Even so, they already
want to start talking about the assays, to understand what
our capabilities are and make sure that we are the best
partner for their clinical development program. It's a
testament to our team's agility that it is able to rapidly
recalibrate to work in such a different way. And I think it is
evidence of Nexelis' reputation for excellence that these
companies are reaching out to us so early, trusting that our
experts will be able to meet their needs.”
Kulnis believes that the global response to the
widespread health threat of COVID-19 has triggered a
drastic change in how companies conduct their work. It
remains to be seen if these changes are temporary, or
the dawn of a new era of increased cooperation.
He says, “In the past, companies went at it on their own,
trying to 'win the race' for a new drug or vaccine out of a
desire to be the first on the market. However, with the
urgency of this pandemic, everyone is inclined to work
together on collaborative projects. The focus seems to be
less on profits, and more on saving lives. It's
understandable: everyone has been affected by this disease
in some way, meaning that we are all have a personal
incentive for trying to fight it.
Companies like Sanofi-Pasteur and GSK, Pfizer and
BioNTech, and Medicago and GSK are working together in
their response to the ongoing pandemic. It has been an
interesting situation, because the level of secrecy and
ownership of various aspects of the development process
have been stripped away. A lot of people have understood
that, in order to accelerate the timelines, they need to be
more collaborative. There has been more willingness to
share information, from general knowledge to technology.
Furthermore, the speed at which licensing agreements have
been processed has been absolutely amazing! We've also
seen an increase in the sharing of materials needed to
benchmark how your product is performing compared to
others.
Philanthropic agencies like CEPI and the Bill and Melinda
Gates Foundation are also providing further incentives for
cooperation by funding collaborative projects. I think this
general spirit of increased collaboration will be a lasting
improvement, even if companies will likely revert a little bit
when it comes to certain proprietary information. At
Nexelis, we definitely see this as a really positive change in
the industry, in line with our own mission of making a
difference to patients.”
People's Health at Core
People's health is at the heart of the Nexelis' mission,
with the company contributing to lifesaving efforts by
supporting pharmaceutical and biotech companies in
the development of vaccines and large molecules. With
a firm grasp of the needs of both sides of the
client/CRO relationship, Nexelis has been instrumental
in the development, qualification, validation and large-
scale sample testing of assays that supported the FDA
filing of almost 100 new molecular entities, including
blockbuster vaccines and soluble large molecules.
Nexelis' versatile team of scientists, using advanced
technology platforms, supports work ranging from
preclinical to clinical Phase I – IV, meeting the ever-
“An inspiring mission is the most powerful motivator there is. And at Nexelis,
we are part of overcoming some of the world's most difficult healthcare
challenges.”
“

25. COVER STORY
Luc Gagnon
VP Vaccine Sciences

26. Facilities
Laval, Canada
BSL2/BSL2+ laboratories and
animal facilities. Focus Infectious
diseases and Immuno-oncology.
20 years legacy in vaccines
R&D and protein sciences
In vivo / in vitro preclinical
High-throughput GCLP preclinical
and clinical testing
Seattle, USA
State-of-the-art laboratories.
Focus on metabolic diseases
and oncologic diseases. BSL2
lab extension plan focusing on
infectious disease to be
implemented
Commercial kits validation
CAP/CLIA & NYDOH
(biomarkers)
GLP/GCP standards
(bioanalytical)
AIT Biosciences
Indianapolis, USA
Paperless FDA inspected state-of-
the-art 19,000 sq. ft laboratories with
LBA and LC-MS/MS platforms
R&D Bioanalytical and
Mass Spectrophotometry
Preclinical and clinical testing
GLP/GCP standards
(Bioanalytical)
America

27. Facilities
ImmunXperts
Gosselies,
Belgium
BSL2/BSL2+ laboratories dedicated
to early stage projects and R&D
Early stage in silico and in vitro
BSL2/BSL2+ laboratories
Biobanking license (PBMC)
Public Health England
Porton Down, UK
BSL2/BSL3/BSL4 laboratories and animal
facilities under the leadership of world class
KOLs
Academic and commercial R&D
GLP testing small scale
BSL2/BSL3/BSL4 animal facility
Europe

28. growing demand for techniques to assess humoral,
innate and cell-mediated immunity induced by
candidate vaccines and immunotherapies.
By adhering to a strong focus on rigorous scientific
discipline and robust protocols, supported by cutting-
edge technological platforms, the firm addresses even
the most demanding client requirements. Unlike huge
generalized CROs who focus on global coverage and
logistic capabilities, the scientific leaders at Nexelis
focus on versatility and ingenuity, enabling the
company to provide highly specialized laboratory
testing services.
At Nexelis, all projects are run in a collaborative client-
centric way, and the agility of Nexelis' team means that
urgent projects can be tailored to meet expedited
timelines. By avoiding overlong processes or heavy
hierarchy, Nexelis' specialists exchange ideas with
colleagues and partner with clients in a collaborative
and transparent manner.
Consequently, the company is recognized for its
scalable operational model, resulting in optimal
flexibility for its clients and high throughput capabilities
for supporting large, global studies.
Turning Challenges into Opportunities
Nexelis' flexibility and work ethic has been put to the
ultimate test during the COVID-19 pandemic. The
company has been supporting the massive R&D efforts
within the international community and has
demonstrated its leadership in the infectious diseases
field through multiple collaborations. Nexelis is
cooperating with almost all multinational sponsors and
innovative biotechnology companies combatting the
SARS-CoV-2 virus.
Furthermore, the company has been selected by the Bill
and Melinda Gates Foundation as the referral
laboratory for all their COVID-19 grantees,
representing hundreds of millions of dollars in research
funding.
In an extraordinarily short amount of time, Nexelis has
dedicated more than 40 scientists to new SARS-CoV-2
developments. This was achieved without pausing any
other strategic vaccine development programs in fields
such as meningitis, flu (seasonal and universal),
Chikungunya, RSV, and malaria.

29. COVER STORY
The company responded rapidly to emerging health
threats thanks to the agility of its scientists and cause
of its portfolio of services in-house. For vaccines and
therapies for COVID-19, as for a large range of other
challenging diseases, Nexelis is proud to partner with
companies looking for patient solutions.
The Differentiating Factor
One of the key advantages in favor of Nexelis is agility,
where an abundance of critical thinking from open
minds compress time and achieve rapid results. There's
no doubt about other CRO companies being positioned
to address the mainstream clinical opportunities,
however, advanced laboratory testing is all on another
level where companies need collaboration with
companies like Nexelis.
Nexelis excels by combining robust protocols and
scientific discipline with human resourcefulness to
quickly tackle even the most demanding of challenges
in the collaborative client partnerships. This
combination of scientific, technological, and human
strengths is what makes Nexelis special.
A Culture that Harbors Innovation
The team at Nexelis offers a distinctive approach
centered on this openness to creativity and innovation
which has rendered the company to be very flexible in
its pursuits. Mr. Bouche has always tried to promote a
culture that encourages specialists to collaborate freely
with colleagues and partners with clients in a spirit of
collaboration and transparency. As a result, there's no
overlong process or heavy hierarchy.
As a state-of-the-art CRO, scientific discipline is at the
heart of every project, supported by the advanced
facilities and cutting-edge technology. At Nexelis, a
truly translational scope of services answers the many
scientific questions that arise from the lead selection
stage through to phase III clinical trials.
Nexelis' in vitro analytical platforms include
immunochemistry, cellular immunology, viral and
bacterial functional assays, as well as flow cytometry,
ELISpot, and PCR/qPCR platforms. The in vitro
laboratory tests are further supported by the in silico
and in vivo teams (in house BSL2 and preclinical
facilities) and a protein sciences group.
Every year, the firm invests millions in new systems and
platforms ensuring that the labs are up to date with the
latest technological advancements.
A More Collaborative Future
In the past few years, Nexelis has developed into a
world-class organization. It has partnered up with the
global top 10 pharmaceutical companies. And for the
forthcoming years, the foundations are already in place
for the organization.
With deep unyielding roots in GSK, Nexelis has already
become the #1 CRO for vaccinology, and now visions to
becoming the choice of partner in other areas as well. It
also wants to expand the scope of services to become a
one-stop shop for companies working on anything from
early development to late clinical stage.
“In every project, we strive to be an extension of
our partner's lab. We're not a CRO where it's 'our
way or the highway'.”
“

31. 1 Year
12 Issues
$250
6 Months
6 Issues
$130
3 Months
3 Issues
$70
1 Month
1 Issue
$25
CHOOSE OUR SUBSCRIPTION
Stay in the known.
Subscribe to CIOLOOK
Get CIOLOOK Magazine in print, and
digital on www.ciolook.com

34. Setting benchmarks in patient outcomes
BSV
32
| December 2020 |

35. 33
| December 2020 |

36. "BSV really lives up to its
logo tagline - Bringing
Life to Life"
-Dr. Mugdha M Raut
“I’ve known BSV since I started my practice in 1992. It is a
leading biopharma company with unique, innovative
products with no compromise on quality and efficacy. I've
met people that have worked for long with them and it
speaks volumes about the company's culture. It also
promotes educational activities in the field of obstetrics
and gynaecology. BSV really lives up to its logo tagline -
Bringing Life to Life” - Dr. Mugdha M Raut, Dr. Raut's
Women's Hospital, Mumbai.
Chairman of AMCHAM Pharma committee (American
Chamber of Commerce) from 2016 to 2019 and Chairman,
Medical and Regulatory Committee from 2016 to 2019. He
has been on the Academic Board of NMMIS Pharma
management, IES Management school and IIHMR, Jaipur.
He is also a management committee member of the well-
known Victoria Memorial School for the Blind, Mumbai.
34
| December 2020 |

38. 36
| December 2020 |

39. 37
| December 2020 |

40. 38
| December 2020 |

42. The need for
multi-site Phase
I studies is
driven by a
trend towards
hybrid studies
exploring drug
effects in
patients
“
Zori Cheshmedzhieva
Vice President, Global
Clinical Development
40
| December 2020 |

43. MDS Pharma Services and Harris
Laboratories, and, thus, we can rely
on more than 40 years of experience
in this field. Today, Celerion is the
leader in accelerating drug
development for Phase I–IIb.
As one of the world's leading CROs
in early clinical development, we
offer clinical services ranging from
First-in-Human studies to Proof-of-
Concept and larger Phase II studies.
These are exactly the stages of drug
development during which our
clients need to make critical go-no-
go decisions on their investigational
products. Any further investments
in the candidate drugs are strongly
driven by early signals of drug
efficacy, in addition to favorable
safety profiles. Celerion has a
unique combination of
competencies allowing it to extend
exploration of drug effects from
healthy volunteer studies to patient
populations. We recruit healthy
subjects in our internal clinics and
through our network of external
sites – but we also execute studies in
patients at our in-house or
partnering clinics.
What measures have you taken to
stay one step ahead of your
competition?
Well, irrespective of COVID-19, we
have always been able to innovate
our services over the years and
optimally adapt to the needs of ours
clients. But 2020 is the year that
COVID-19 changed the world,
including the way trials can and
should be conducted. So perhaps
the way we adapted our services
illustrates our ability to adapt our
operations swiftly and remain a
leading provider of early clinical
research services.
In response to the pandemic, we
immediately drew up Risk
Mitigation Plans and incorporated
novel working procedures and
facility changes to accommodate
COVID-19 concerns, all in line with
regulatory guidelines and local
public health regulations. We also
implemented a broad package of
protective measures for the safety
of both study participants and staff
and created more bed and lab space.
Altogether, these measures enabled
us to re-open our clinics and resume
trial activities in May of this year.
Our bioanalytical labs, which have a
long standing experience with
vaccine-related analyses, have
developed various assays in the
context of COVID-19, ranging from
PCR tests for SARS-CoV-2 to
specific antibody assessments for
IgG, IgM e.g. against the Spike
protein – not only to enable in-
Translating Scientific Ideas into
Potential Medicines
C
elerion is a premier global
provider of early clinical drug
development services to the
pharmaceutical industry, and its
track record spans both preventive
and therapeutic vaccines, subunit,
and conjugates, as well as antiviral
agents and (passive) antibody
therapies across all phases I-IV in
more than 20 countries, 300 study
centers and over 5000 subjects.
Zori Cheshmedzhieva Vice
is the
President, Global Clinical
Development at Celerion. She is
leading Celerion Global Clinical
Development services across
Europe and North America with
direct line management of
Operational team including Project
management, Budgeting and
Proposal preparation, Feasibility
and start-up, Site management.
When was Celerion founded and
what is its current market position
like?
This year, Celerion is celebrating its
10th anniversary. When founded in
2010, the name Celerion was
derived from the Latin word
celeritas, meaning swiftness and
speed, to reflect the high quality,
speed, and efficiency of services
that we provide. Our early clinical
development and bio-analytical
divisions are built upon the legacy of
41
| December 2020 |

44. house screening for infection, but in particular to
support the development of vaccines and anti-viral
drugs targeting COVID-19.
Moreover, due to the impact of COVID-19 clinical trial
conduct, a rapid expansion of virtual clinical trials was
made. These trials take full advantage of virtual
technologies (apps, monitoring devices, etc.) and online
social engagement platforms to conduct aspects of
each stage of the clinical trial from the comfort of the
patients' home. This includes recruitment, informed
consent, patient counselling, as well as measurements
of clinical endpoints through deployment of wearables,
ePRO and other tools/devices. We assist our clients in
determining the most appropriate approach for their
study, ranging from fully virtual to traditional trial
execution.
How did the landscape of clinical trials change and
how relevant was that for your role?
Celerion has always focused on the earlier stages of
clinical drug development, in addition to bio-analytical
services.
In the 10 years of its existence, the need for multi-site,
exploratory studies has steadily increased. On the one
hand, this reflects a trend towards hybrid studies,
combining conventional safety and tolerability studies
with early exploration of drug effects in patients.
On the other hand, vaccine trials do not necessarily
need the highly specialized clinical research unit
environment that many Phase I trials demand and may
also recruit faster if multiple sites enroll participants.
With solid background in clinical trial management
my
organizations, I have been able to strengthen Celerion's
global operations, expand the site networks and add
efficiencies to the setup and conduct of trials. In
particular, my expertise has been extremely useful in
the seamless integration of in-house operations and
external site management. With regard to trials
evaluating vaccines and antiviral drugs, for instance,
this is key when extending early studies in healthy
volunteers to larger or special populations, such as
elderly and health care workers.
One of our key approaches towards building
relationships with potential clients is to showcase our
scientific expertise and operational experience with the
setup and conduct of exploratory Phase I and II trials.
Although a personal interaction is our preferred way to
connect with new customers, presentation of case
studies at conferences often helps trigger the interest
of its clients. With conferences going virtual because of
the pandemic, we contributed to various discussions
over the past months.
Being the world's leading provider of early clinical
trial services, what makes Celerion so unique?
Over the years, our Phase I bed capacity has grown to
the largest in the world, which in combination with
complex methodologies, trial site networks, ECG Core
Lab and bio-analytical lab services enables us to
provide drug development services that accelerate the
translation of scientific ideas into potential medicines.
Achieving clinical Proof-of-Concept is a critical
milestone for drug candidates, and we help clients
define what a successful clinical proof-of-concept study
should entail. When a sponsor demonstrates that a
drug works in humans as anticipated from preclinical
data, their drug acquires real value.
42
| December 2020 |

45. For many drugs, such as antiviral agents, after initial
evaluation in healthy subjects, Phase Ib and hybrid
studies are conducted. These studies usually enroll
patient cohorts to measure biomarkers that represent
pathophysiological pathways that a drug is targeting.
Thus, value is added by providing early signals of drug
effects in the target population in the earliest stage of
drug development.
For the development of prophylactic vaccines, Celerion
has established innovative methods, for example to
determine the percentage of functional antibody
capable of producing a therapeutic effect, neutralizing a
virus or toxin, or eliciting a specific immune cell
response to enable, which can be applied to establish
Proof of Concept in healthy volunteers.
Our innovative solutions set Celerion apart as a leading
early-phase CRO, but we realize that ongoing advances
are required to maintain that leadership position. Much
of our strategy will focus on accelerating drug
development up to Proof-of-Concept, by integrating
early patient studies and biomarker development. The
latter will encompass identification of biomarkers for
new drug targets and method development featuring
bio-analytical technologies like ELISpot and flow
cytometry. Implementation of new technologies will
contribute to virtual data management processes as
well as to sophisticated sampling and detection
methods to accelerate clinical conduct.
By using our expertise in biomarkers and clinical study
design and conduct, we also believe that Celerion has
an important role to play towards future modalities for
curing diseases rather than treating symptoms, such as
cell-based therapies and 3D-printed tissues or organs.
We take pride in many of our clients referencing
Celerion when presenting their clinical trial data at
scientific conferences or when publishing in peer-
reviewed journals.
With the volatile technological changes, what
measures is the company taking to boost its growth?
It's absolutely true that technological advancements
are a key driver of innovation in clinical trial conduct
and in fact Celerion has always been an early adopter of
new technologies. For instance, we were at the
forefront of highly automated electrocardiogram
overread, and Celerion's laboratories were the first to
move completely to electronic lab notebooks.
For Celerion, the implementation of virtual
technologies have diminished the burden of in-house
operations, especially during the COVID-19 pandemic
requiring social distancing and stringent infection
prevention measures, and have also facilitated the
conduct of trials across multiple sites and geographies.
As a result, we have been able to stabilise our in-house
trial operations and grow our external trial capacity.
Apart from the shift to virtual trial conduct, at Celerion
we have implemented the Veeva platform to achieve an
interconnected and fully automated virtual
environment for data management, with direct live
access to study status and monitoring of data, trial files
and documentation (eTMF) and direct access to sites
data. This platform for instance allows straightforward
tracking of study milestones and software integration
enabling remote Source Data Verification and
monitoring, thereby increasing efficiencies and data
quality capture in any type of clinical trial – virtual,
hybrid or traditional.
43
| December 2020 |

47. 45
Healthcare Viewpoint
| December 2020 |

48. 46
| December 2020 |

50. Mike Suga
President & CEO
CMIC, Inc.
48
| December 2020 |

51. CMIC, Inc.
Ascending Zeniths of Global Success
So important are laboratories in the creation and
development of drugs worldwide that today the likes of
CMIC, Inc, a global contract laboratory aren't taken to
be an outsourced entity but are treated as an integral
element in the working of pharmaceutical companies
worldwide. With the pandemic having driven humanity
to cower behind closed doors and high walls, and every
conceivable lab trying to churn out a vaccine, CMIC
Inc's activities have an added significance of finding
decisive and long-term succour for humanity.
Speaking of activities and services to the
pharmaceutical industry, CMIC's most significant
offering happens to be in the area of Bioanalysis that
finds application in clinical and other pharmaceutical
related studies, and includes method development,
method transfer, method qualification, method
validation, cross-validation and sample analysis. Due to
the range of services under Bioanalysis, it remains a
critical element to drug development in the pharma
industry.
With over 30 years of expertise as a leading Contract
Research Organization (CRO) and a provider of
specialized bioanalytical services to research CMIC Inc.
provides cutting-edge expertise to pharmaceutical
companies in their small and large molecule bioanalysis
in order to optimize the latter's drug development
activity. To this end, CMIC, Inc provides bioanalysis for
nonclinical and clinical projects, both GLP and non-GLP,
to meet critical drug development milestones. Its GLP
compliant state-of-the-art facility can accommodate
quick turn around and high-volume projects.
“Without laboratories, men of
science are soldiers without arms!”
So said Louis Pasteur, Chemist and Microbiologist
par-excellence on the subject of laboratories.
49
| December 2020 |

52. Those in the know attribute the reason for CMIC Inc's
high efficiency and incisiveness to its origins. A
significant off-shoot of Japan's formidable first and
largest Contract Research Organization (CRO) and also
the top bioanalysis lab, the CMIC Group, the former
was established as a strategic cornerstone for CMIC
Group's growth prospects in the North American
pharma sector.
CMIC Inc was established with a vision to provide the
"Pharmaceutical Value Creator" (PVC) service
encompassing the entire value-chain of pharmaceutical
companies to include not just CRO, but also
manufacturing, sales, and marketing services. In doing
so, they remain the leading bioanalysis CRO in
oligonucleotide therapeutics (Oligo) for several years
now who remain extremely flexible and agility with
quick turn-around times- a forte not found in most
large CROs.
Their 3 plus decades of experience in the field has
earned them a name in conventional small molecule
research and they are in the process of significantly
expanding their capabilities in large molecule and
biomarker. Marking their presence in the field as also
getting them their clients' attention are several
scientific publications and whitepapers and several
webinars either already implemented or planned by
CMIC, Ind together with the rest of CMIC Group.
If there is anything that mirrors CMIC. Inc's growth
story, it is that of its President and CEO Mike Suga.
With 3+ decades in the industry that matches that of
the group, he came into the CMIC fold in the year 2015.
With significant and commendable experiences across
fields including biotechnology, pharmaceuticals, life
sciences and medical devices, he is more than a known
figure in the industry.
With a Bachelor and then a Master's degrees in
agricultural biosciences from the University of Tokyo,
Mike started his 30-year's professional career as tissue
culture and genomics scientists at JT genetic
engineering lab and later spent 5 years in New York and
San Francisco as JT's recombinant DNA business
development manager. He was also the Deputy General
Manager of GE's Healthcare's CT/MRI contrast media
in vivo diagnostics and PET/SPECT radio-
pharmaceuticals division in Japan and was responsible
for establishing a new pharmaceutical operation
reporting into GE Healthcare's U.K Headquarters.
50
| December 2020 |

53. Complementing Mike's efforts is the leadership team at
CMIC. With experience ranging from 15 to 25+ years,
they are helping the company grow and address the
bioanalysis CRO needs of mid-to-small/bio ventures
who were never the target clientele pf larger CROs.
Together the current leadership team has also
competed the strategic facility investment in 2017,
leveraged by CMIC's new U.S. client base expansion
after business integration. At CMIC, Inc., we will
accelerate our growth of services in North America and
most importantly better aligns with our overall vision to
bring value with each client interaction," so says a
charged Mike Suga. Based in Chicago, Mike also serves
as the Senior Vice President of CMIC HOLDINGS Co.,
Ltd., reporting directly to CMIC Group's Tokyo
Headquarters. “
Despite Mike's initiatives and CMIC, Inc's formidable
presence and activities, the industry remains a volatile
place with newer technologies and methodologies
making their presence at regular intervals. To address
these and evolve themselves to address customer
needs has been CMIC's "CREED", a corporate
philosophy that is about considering the Wellbeing,
Challenge, Change and Communication (W&3Cs) any
opportunity might bring. Mike and his team apply the
philosophy with marked seriousness to evolve
themselves in line with market changes and the voices
of customers.
If there is one word which best describes the future, it
is volatility which as a phenomenon affects everyone in
every situation. To this end CMIC, Inc and Mike's team
plan to expand their scope from the current
"Pharmaceutical Value Creator" (PVC) business model
to an aspirational "Personal Healthcare Value Creator"
(PHVC) which would see them contribute to and
address the up-coming personalized medicine and
individual quality of life among patients. A great
decision given that the ultimate aim of any
pharmaceutical initiative, including of those of their
subsidiary entities, is to be of use to individual patients.
“
“We have an aspiration to
become a “Personal
Healthcare Value Creator”
(PHVC) to contribute for and
to address to the up-coming
personalized medicine and
individual patient quality of
life.”
51
| December 2020 |

54. New Horizons
O
ver the coming years, we expect
pharmaceutical industry models to be
reshaped by some forces both from within
and outside of the industry - that will demand
present organizations to recognize shifting
markets and figure out how they will compete in
the changing market.
Biopharmaceutical companies will continue to
evolve in new ways to treat and cure a variety of
diseases. However, in the future actionable health
insights, driven by artificial intelligence and big
data analytics, can help doctors and patients to
identify illness much quicker than the time we
require today. In the first place, the newly invented
vaccines and other early interventions due to
technological advancements could prevent a
greater number of illnesses from developing.
Other diseases can be also prevented. Changes in
how diseases are recognized, prevented,
diagnosed, treated, or cured might lead to
basically different business models for traditional
pharmaceutical companies.
The future of health that we will witness in the
upcoming years will be much different from what
we have now. Based on evolving technologies, we
can be sure that digital transformation driven by
big data analytics, artificial intelligence, and
through such secure platforms will be key in
leading this change. Unlike today, we can expect
that care will be streamlined around the patients,
rather than around the institutions that drive our
current health care system.
In the next few years, streams of healthcare data,
combined with data from a variety of other
relevant resources will probably merge to create a
multifaceted and highly personalized picture of
the well-being of every patient. Many digital
health organizations have already started to
incorporate biosensors and software into devices
that can create, gather, and integrate data.
Advanced cognitive intensive technologies can be
developed to analyze a precisely large set of
parameters and create personalized insights into
the health of the patients. The availability of
streamlined data and personalized AI can enable
much precise well-being and actually real-time
micro-interventions that will allow us to get ahead
of illness and far ahead of catastrophic or chronic
disease. By 2040, health is much more likely to
revolve around preventing some illnesses from
happening and curing others. Fewer people might
have long-term conditions or chronic disabilities
with a continued need for medicines to treat
symptoms.
The few factors that may be the most important
component of shaping the future of
pharmaceutical industry can be prevention or
recognition and early detection, streamlined or
customized treatments, curative therapies, digital
therapeutics, and precision intervention.
Prevention and early detection: Vaccine and
general improvements in wellness could help
prevent illnesses, making treatment for some
illnesses no longer essential. Progress in early
detection will more likely enable interventions
that halt diseases in the beginning stages before
they progress to become more serious or chronic
conditions.
Customized treatments: Personalised services in
medicine driven by data-powered insights can
effectively match patients with customized drug
medicines or design therapies that will work for
just a few people or even a specific person. More
customized treatments will be the most important
part of the pharmaceutical industry in the future.
Curative therapies: As with prevention,
treatments that cure the illnesses can decrease or
eliminate the demand for some prescription
medicines. Developing, marketing, and costing of
these curative treatments may require the
pharmaceutical sector to adopt new capabilities
and strategies.
52
| December 2020 |

55. EVOLVING
FUTURE OF THE
BIOPHARMACEUTICAL
INDUSTRY
53
| December 2020 |

58. 56
| December 2020 |

59. 57
Tech Outlook
| December 2020 |

60. 58
| December 2020 |

61. 59
| December 2020 |